ClinicalTrials.gg
CompletedNCT04590430Updated Mar 11, 2022

Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults

A Phase 1 interventional study of HFB30132A and Placebo in Healthy, sponsored by HiFiBiO Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-11.

Sponsored by HiFiBiO Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2021, 5 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to test the safety and tolerability of HFB30132A when it is given by intravenously to healthy participants. Blood tests will be done to check how much HFB30132A is in the bloodstream and how long the body takes to eliminate it. Participation may include up to ten visits to the study center.

Read the detailed description

This is a Phase I, first time in human, randomized, double-blind, placebo-controlled, and dose escalation study in healthy volunteers.

The study will comprise of:

  1. A Screening Period of up to 30 days (Day -30 through Day -1);
  2. A Treatment Period during which participants will be resident at the Observation Unit from Day -1, 1 day before Investigational Medicinal Product (IMP) administration (on Day 1) until at least 24 hours after IMP administration, will be discharged on Day 2 after all safety and/or pharmacokinetic (PK) evaluations have been completed, and
  3. A Follow up Period lasting 180 days after the IMP dose. The study will be conducted at a single study center in Cincinnati.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HiFiBiO Therapeutics is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a healthy male or female subject, aged between 18 to 60 years (both inclusive). Health is defined as no abnormalities identified by Investigator's decision based on a detailed medical history, full physical examination, including blood pressure, heart rate, respiratory rate, and body temperature measurement, (ECG) and clinical laboratory tests prior to the study drug administration.
  • Subject is confirmed as negative by SARS-CoV-2 RT-PCR testing on screening and prior to admission to the unit.
  • Subject voluntarily agrees to participate in this study and has given written prior to undergoing any of the screening procedures.
  • Willing and able to comply with all scheduled visits, treatment plan, clinical laboratory tests, lifestyle guidelines, methods of , including COVID-19 social distancing guidelines as described in Section 5.7.2 (under "Hygiene") from signing of informed consent through end of study on Day 180.
  • Female subjects of must not be planning a pregnancy or be pregnant or lactating. All female subjects must have a negative result for the pregnancy tests performed at screening and admission.
  • Female subjects of childbearing potential (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of contraception until study completion and for at least 4 weeks following their final study visit on Day 180. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as hormonal contraception (oral, implant, injection, ring, or patch) and intrauterine contraceptive devices (IUDs) at least 3 months prior to Screening or a vasectomized partner. Note: Complete abstinence from sexual intercourse is acceptable.
  • Female subject is of non-childbearing potential defined as surgically sterile (i.e. documented bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or at least 12 months (defined with no menses without an alternative medical cause and follicle stimulating hormone test in the post-menopausal range at the screening visit.
  • Male subjects with partners of childbearing potential must have had surgical sterilization (vasectomy) at least 26 weeks prior to screening or use a male barrier method of contraception (i.e. male condom with spermicide) during any sexual intercourse, from Study Day -1 (beginning of confinement) until 3 months after the final Follow-up Visit on Day 270. Note: complete abstinence from sexual intercourse is acceptable.
  • Male subjects must agree to abstain from sperm donation from initial study drug administration through 3 months after the last Follow-up Visit on Day 180.

Exclusion criteria

Exclusion Criteria:

  • History of any illness or history or presence of pathology that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject or collecting samples for analysis. This includes, but is not limited to, a history of relevant drug or food allergies; history of clinically significant cardiovascular, pulmonary, , psychiatric or central nervous system disease, or of cancer with systemic spread in remission for less than 5 years.
  • Use of any medications started within 14 days (or 5 half-lives, whichever is longer) prior to study drug administration including, prescription medications, nutritional supplements, and over-the-counter medications except for vitamin supplements, hormonal , and recommended doses of acetaminophen, aspirin or ibuprofen
  • Hospitalization for any reason within 60 days prior to the screening visit
  • History of or positive (HIV) screen result, or positive blood test for surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Subjects with positive virus (HCV) antibody at the screening visit are only eligible if they have previously completed treatment for HCV and have confirmatory negative test for HCV RNA.
  • History of drug or alcohol abuse within 1 year prior to screening, or positive test for drugs of potential abuse at screening and admission, where alcohol abuse is defined as regular consumption exceeding 7 drinks/ week for women, and 14 drinks/ week for men.
  • Participation (defined as receipt of dose of agent) in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer), of the investigational drug prior to the screening visit
  • Blood donation of approximately 1 pint (500 mL) within 60 days prior to dosing, or donation of more than 1 unit of plasma within 30 days prior to the start of study drug dosing
  • Receipt of any transfused blood products within 60 days of the screening visit.
  • Any history of receiving treatment or vaccination against SARS-CoV-2
  • Febrile illness within 28 days prior to the first dose of study drug, or other signs or symptoms consistent with SARS-CoV-2 infection in the judgement of the Investigator in the 14 days prior to the first dose of study drug.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    HFB30132A

    Participants will receive HFB30132A administered across 3 fixed-dose cohorts via intravenous infusions (to be administered sequentially)

    Drug: HFB30132A

  • Placebo comparator
    Placebo

    Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.

    Other: Placebo

Interventions

  • DrugHFB30132A

    Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.

  • OtherPlacebo

    Participants randomized to placebo will receive the same volume of solution as participants on active treatment.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment emergent serious adverse events (TESAEs)

    Number of participants experiencing TEAEs

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

  2. Number of participants with treatment emergent adverse events (TEAE) of special interest

    Safety and tolerability will be evaluated in terms of number of participants with TEAEs of special interest (hypersensitivity / anaphylactic reaction / local tolerability)

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

  3. Number of participants with treatment-emergent adverse events (TEAE)

    Safety and tolerability will be evaluated in terms of number of participants with TEAE

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

  4. Maximum observed serum concentration (Cmax)

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

  5. Minimum observed serum concentration (Cmin)

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

  6. Time of maximum serum concentration (Tmax)

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

  7. Area under the concentration vs. time curve (AUC0-last), AUC0-∞)

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

  8. Terminal half-life (T1/2)

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

  9. Systemic clearance (CL)

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

  10. Steady-state volume of distribution (Vss)

    Time frame: From Day 1 to up to Day 30 of the last enrolled subject

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Safety and tolerability will be evaluated in terms of number of participants with TEAEs

    Time frame: From Day 1 to up to last follow-up day (Day 180)

  2. Number of participants with treatment-emergent serious adverse events (TESAEs)

    Safety and tolerability will be evaluated in terms of number of participants with TESAEs

    Time frame: From Day 1 to up to last follow-up day (Day 180)

  3. Maximum observed serum HFB30132A concentration (Cmax) in nasal and oral secretions

    Time frame: From Day 1 to up to last follow-up day (Day 180)

  4. Minimum observed serum HFB30132A concentration (Cmin) in nasal and oral secretions

    Time frame: From Day 1 to up to last follow-up day (Day 180)

  5. Time of maximum serum HFB30132A concentration (Tmax) in nasal and oral secretions

    Time frame: From Day 1 to up to last follow-up day (Day 180)

  6. Area under the concentration vs. time curve (AUC0-last), AUC0-∞) in nasal and oral secretions

    Time frame: From Day 1 to up to last follow-up day (Day 180)

  7. Terminal half-life (T1/2) of HFB30132A in nasal and oral secretions

    Time frame: From Day 1 to up to last follow-up day (Day 190)

  8. Systemic clearance (CL) of HFB30132A in nasal and oral secretions

    Time frame: From Day 1 to up to last follow-up day (Day 180)

  9. Steady-state volume of distribution (Vss) of HFB30132A in nasal and oral secretions

    Time frame: From Day 1 to up to last follow-up day (Day 180)

  10. HFB30132A Anti-drug antibodies

    Presence or absence of antibodies against HFB30132A over time

    Time frame: From Day 1 to up to last follow-up day (Day 180)

07

Study locations

1 site
  • Medpace Clinical Pharmacology Unit
    Cincinnati, Ohio 45227, United States
08

References and documents

Publications

  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. PubMed 34473343 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jul 2021, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2020
First posted
Oct 19, 2020
StartActual
Oct 20, 2020
Primary completionActual
Jul 26, 2021
CompletionActual
Jul 26, 2021
Last update
Mar 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04590430
Lead sponsor
HiFiBiO Therapeutics
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Oct 20, 2020
Primary completion
Jul 26, 2021
Completion
Jul 26, 2021
Last update
Mar 11, 2022

Study contacts

Leela Vrishabhendra, MD
principal investigator · Medpace, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion